Advertisement

The Impact of Proton Pump Inhibitors on the Human Gastrointestinal Microbiome

Published:September 25, 2014DOI:https://doi.org/10.1016/j.cll.2014.08.008

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Dorlencourt H.
        • Lavaudon R.
        Les pH des selles des nourrissons sains et malades.
        Nourrisson. 1931; 19: 147-153
        • Evans D.F.
        • Pye G.
        • Bramley R.
        • et al.
        Measurement of gastrointestinal pH profiles in normal ambulant human subjects.
        Gut. 1988; 29: 1035-1041
        • Berk L.
        • Castle W.B.
        • Welch A.D.
        • et al.
        Observations on the etiologic relationship of achylia gastrica to pernicious anemia; activity of vitamin B12 as food, extrinsic factor.
        N Engl J Med. 1948; 239: 911-913
        • Fallingborg J.
        Intraluminal pH of the human gastrointestinal tract.
        Dan Med Bull. 1999; 46: 183-196
        • Said H.M.
        • Redha R.
        • Nylander W.
        Biotin transport in the human intestine: site of maximum transport and effect of pH.
        Gastroenterology. 1988; 95: 1312-1317
        • Strum W.B.
        Enzymatic reduction and methylation of folate following pH-dependent, carrier-mediated transport in rat jejunum.
        Biochim Biophys Acta. 1979; 554: 249-257
        • Lam J.R.
        • Schneider J.L.
        • Zhao W.
        • et al.
        Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency.
        JAMA. 2013; 310: 2435-2442
        • Carmel R.
        • Rosenberg A.H.
        • Lau K.S.
        • et al.
        Vitamin B12 uptake by human small bowel homogenate and its enhancement by intrinsic factor.
        Gastroenterology. 1969; 56: 548-555
        • Feldman M.
        • Friedman L.S.
        • Sleisenger M.H.
        Sleisenger & Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management.
        7th edition. Saunders, Philadelphia2002
        • Munson K.
        • Lambrecht N.
        • Shin J.M.
        • et al.
        Analysis of the membrane domain of the gastric H(+)/K(+)-ATPase.
        J Exp Biol. 2000; 203: 161-170
        • Chiba T.
        • Malfertheiner P.
        • Satoh H.
        Proton pump inhibitors: a balanced view.
        Karger AG, Basel (Switzerland)2013
        • Larsson H.
        • Carlsson E.
        • Mattsson H.
        • et al.
        Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats.
        Gastroenterology. 1986; 90: 391-399
        • Olbe L.
        • Carlsson E.
        • Lindberg P.
        A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.
        Nat Rev Drug Discov. 2003; 2: 132-139
        • Sim S.C.
        • Risinger C.
        • Dahl M.L.
        • et al.
        A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.
        Clin Pharmacol Ther. 2006; 79: 103-113
        • Kahrilas P.J.
        • Shaheen N.J.
        • Vaezi M.F.
        • et al.
        American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease.
        Gastroenterology. 2008; 135 (1391.e1–5): 1383-1391
        • Shin J.M.
        • Munson K.
        • Vagin O.
        • et al.
        The gastric HK-ATPase: structure, function, and inhibition.
        Pflugers Arch. 2009; 457: 609-622
        • Laine L.
        • Shah A.
        • Bemanian S.
        Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers.
        Gastroenterology. 2008; 134: 1836-1841
        • Gan K.H.
        • Geus W.P.
        • Lamers C.B.
        • et al.
        Effect of omeprazole 40 mg once daily on intraduodenal and intragastric pH in H. pylori-negative healthy subjects.
        Dig Dis Sci. 1997; 42: 2304-2309
        • Michalek W.
        • Semler J.R.
        • Kuo B.
        Impact of acid suppression on upper gastrointestinal pH and motility.
        Dig Dis Sci. 2011; 56: 1735-1742
      1. IMS Health. Top-Line Market Data. Available at: http://www.imshealth.com/portal/site/ims/menuitem.5ad1c081663fdf9b41d84b903208c22a/?vgnextoid=fbc65890d33ee210VgnVCM10000071812ca2RCRD. Accessed March 23, 2014.

        • Heidelbaugh J.J.
        • Goldberg K.L.
        • Inadomi J.M.
        Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected].
        Am J Gastroenterol. 2009; 104: S27-S32
        • Zink D.A.
        • Pohlman M.
        • Barnes M.
        • et al.
        Long-term use of acid suppression started inappropriately during hospitalization.
        Aliment Pharmacol Ther. 2005; 21: 1203-1209
        • Bashford J.N.
        • Norwood J.
        • Chapman S.R.
        Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database.
        BMJ. 1998; 317: 452-456
        • Yang Y.X.
        • Metz D.C.
        Safety of proton pump inhibitor exposure.
        Gastroenterology. 2010; 139: 1115-1127
        • Epstein M.
        • McGrath S.
        • Law F.
        Proton-pump inhibitors and hypomagnesemic hypoparathyroidism.
        N Engl J Med. 2006; 355: 1834-1836
        • Markovits N.
        • Loebstein R.
        • Halkin H.
        • et al.
        The association of proton pump inhibitors and hypomagnesemia in the community setting.
        J Clin Pharmacol. 2014; 54: 889-895
        • Vesper B.J.
        • Jawdi A.
        • Altman K.W.
        • et al.
        The effect of proton pump inhibitors on the human microbiota.
        Curr Drug Metab. 2009; 10: 84-89
        • Melchers K.
        • Herrmann L.
        • Mauch F.
        • et al.
        Properties and function of the P type ion pumps cloned from Helicobacter pylori.
        Acta Physiol Scand Suppl. 1998; 643: 123-135
        • Hoskins J.
        • Alborn Jr., W.E.
        • Arnold J.
        • et al.
        Genome of the bacterium Streptococcus pneumoniae strain R6.
        J Bacteriol. 2001; 183: 5709-5717
        • Katz P.O.
        • Gerson L.B.
        • Vela M.F.
        Guidelines for the diagnosis and management of gastroesophageal reflux disease.
        Am J Gastroenterol. 2013; 108 ([quiz: 329]): 308-328
        • Kahrilas P.J.
        • Shaheen N.J.
        • Vaezi M.F.
        • American Gastroenterological Association Institute
        • Clinical Practice and Quality Management Committee
        American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease.
        Gastroenterology. 2008; 135 (1413.e1–5): 1392-1413
        • Dellon E.S.
        • Gonsalves N.
        • Hirano I.
        • et al.
        ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE).
        Am J Gastroenterol. 2013; 108 ([quiz: 693]): 679-692
        • El-Serag H.B.
        Time trends of gastroesophageal reflux disease: a systematic review.
        Clin Gastroenterol Hepatol. 2007; 5: 17-26
        • Pohl H.
        • Welch H.G.
        The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.
        J Natl Cancer Inst. 2005; 97: 142-146
        • Jacobson B.C.
        • Ferris T.G.
        • Shea T.L.
        • et al.
        Who is using chronic acid suppression therapy and why?.
        Am J Gastroenterol. 2003; 98: 51-58
        • Yang L.
        • Lu X.
        • Nossa C.W.
        • et al.
        Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome.
        Gastroenterology. 2009; 137: 588-597
        • Yang L.
        • Francois F.
        • Pei Z.
        Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus.
        Clin Cancer Res. 2012; 18: 2138-2144
        • Fan Y.P.
        • Chakder S.
        • Gao F.
        • et al.
        Inducible and neuronal nitric oxide synthase involvement in lipopolysaccharide-induced sphincteric dysfunction.
        Am J Physiol Gastrointest Liver Physiol. 2001; 280: G32-G42
        • Calatayud S.
        • Garcia-Zaragoza E.
        • Hernandez C.
        • et al.
        Downregulation of nNOS and synthesis of PGs associated with endotoxin-induced delay in gastric emptying.
        Am J Physiol Gastrointest Liver Physiol. 2002; 283: G1360-G1367
        • Liu N.
        • Ando T.
        • Ishiguro K.
        • et al.
        Characterization of bacterial biota in the distal esophagus of Japanese patients with reflux esophagitis and Barrett's esophagus.
        BMC Infect Dis. 2013; 13: 130
        • Amir I.
        • Konikoff F.M.
        • Oppenheim M.
        • et al.
        Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors.
        Environ Microbiol. 2013; https://doi.org/10.1111/1462-2920.12285
        • Rajilic-Stojanovic M.
        • Biagi E.
        • Heilig H.G.
        • et al.
        Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome.
        Gastroenterology. 2011; 141: 1792-1801
        • Wang C.
        • Yuan Y.
        • Hunt R.H.
        Helicobacter pylori infection and Barrett's esophagus: a systematic review and meta-analysis.
        Am J Gastroenterol. 2009; 104 ([quiz: 491, 501]): 492-500
        • Rokkas T.
        • Pistiolas D.
        • Sechopoulos P.
        • et al.
        Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis.
        Clin Gastroenterol Hepatol. 2007; 5 (1417.e1–2): 1413-1417
        • Fischbach L.A.
        • Graham D.Y.
        • Kramer J.R.
        • et al.
        Association between Helicobacter pylori and Barrett's esophagus: a case-control study.
        Am J Gastroenterol. 2014; 109: 357-368
        • Iwahi T.
        • Satoh H.
        • Nakao M.
        • et al.
        Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.
        Antimicrob Agents Chemother. 1991; 35: 490-496
        • Chey W.D.
        • Wong B.C.
        • Practice Parameters Committee of the American College of Gastroenterology
        American College of Gastroenterology guideline on the management of Helicobacter pylori infection.
        Am J Gastroenterol. 2007; 102: 1808-1825
        • Andersson A.F.
        • Lindberg M.
        • Jakobsson H.
        • et al.
        Comparative analysis of human gut microbiota by barcoded pyrosequencing.
        PLoS One. 2008; 3: e2836
        • Sanduleanu S.
        • Jonkers D.
        • De Bruine A.
        • et al.
        Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa.
        Aliment Pharmacol Ther. 2001; 15: 379-388
        • Labenz J.
        • Tillenburg B.
        • Peitz U.
        • et al.
        Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer.
        Gastroenterology. 1996; 110: 725-732
        • Engstrand L.
        • Lindberg M.
        Helicobacter pylori and the gastric microbiota.
        Best Pract Res Clin Gastroenterol. 2013; 27: 39-45
        • Zilberstein B.
        • Quintanilha A.G.
        • Santos M.A.
        • et al.
        Digestive tract microbiota in healthy volunteers.
        Clinics (Sao Paulo). 2007; 62: 47-54
        • Li X.X.
        • Wong G.L.
        • To K.F.
        • et al.
        Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-inflammatory drug use.
        PLoS One. 2009; 4: e7985
        • Cover T.L.
        • Blaser M.J.
        Helicobacter pylori in health and disease.
        Gastroenterology. 2009; 136: 1863-1873
        • Pereira S.P.
        • Gainsborough N.
        • Dowling R.H.
        Drug-induced hypochlorhydria causes high duodenal bacterial counts in the elderly.
        Aliment Pharmacol Ther. 1998; 12: 99-104
        • Houghton J.
        • Wang T.C.
        Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers.
        Gastroenterology. 2005; 128: 1567-1578
      2. IARC working group on the evaluation of carcinogenic risks to humans: some industrial chemicals. Lyon, 15-22 February 1994.
        IARC Monogr Eval Carcinog Risks Hum. 1994; 60: 1-560
        • Wong B.C.
        • Lam S.K.
        • Wong W.M.
        • et al.
        Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.
        JAMA. 2004; 291: 187-194
        • Ma J.L.
        • Zhang L.
        • Brown L.M.
        • et al.
        Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality.
        J Natl Cancer Inst. 2012; 104: 488-492
        • Malfertheiner P.
        • Megraud F.
        • O'Morain C.A.
        • et al.
        Management of Helicobacter pylori infection–the Maastricht IV/Florence Consensus Report.
        Gut. 2012; 61: 646-664
        • Liu W.Z.
        • Xie Y.
        • Cheng H.
        • et al.
        Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection.
        J Dig Dis. 2013; 14: 211-221
        • Dicksved J.
        • Lindberg M.
        • Rosenquist M.
        • et al.
        Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls.
        J Med Microbiol. 2009; 58: 509-516
        • Tan M.P.
        • Kaparakis M.
        • Galic M.
        • et al.
        Chronic Helicobacter pylori infection does not significantly alter the microbiota of the murine stomach.
        Appl Environ Microbiol. 2007; 73: 1010-1013
        • Wang T.C.
        • Dangler C.A.
        • Chen D.
        • et al.
        Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer.
        Gastroenterology. 2000; 118: 36-47
        • Lofgren J.L.
        • Whary M.T.
        • Ge Z.
        • et al.
        Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia.
        Gastroenterology. 2011; 140: 210-220
        • Lertpiriyapong K.
        • Whary M.T.
        • Muthupalani S.
        • et al.
        Gastric colonisation with a restricted commensal microbiota replicates the promotion of neoplastic lesions by diverse intestinal microbiota in the Helicobacter pylori INS-GAS mouse model of gastric carcinogenesis.
        Gut. 2014; 63: 54-63
        • Klinkenberg-Knol E.C.
        • Nelis F.
        • Dent J.
        • et al.
        Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.
        Gastroenterology. 2000; 118: 661-669
        • Lombardo L.
        • Foti M.
        • Ruggia O.
        • et al.
        Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy.
        Clin Gastroenterol Hepatol. 2010; 8: 504-508
        • Pyleris E.
        • Giamarellos-Bourboulis E.J.
        • Tzivras D.
        • et al.
        The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome.
        Dig Dis Sci. 2012; 57: 1321-1329
        • Lo W.K.
        • Chan W.W.
        Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis.
        Clin Gastroenterol Hepatol. 2013; 11: 483-490
        • Bures J.
        • Cyrany J.
        • Kohoutova D.
        • et al.
        Small intestinal bacterial overgrowth syndrome.
        World J Gastroenterol. 2010; 16: 2978-2990
        • Williams C.
        • McColl K.E.
        Review article: proton pump inhibitors and bacterial overgrowth.
        Aliment Pharmacol Ther. 2006; 23: 3-10
        • Wallace J.L.
        • Syer S.
        • Denou E.
        • et al.
        Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.
        Gastroenterology. 2011; 141 (1322.e1–5): 1314-1322
        • Nadal I.
        • Donat E.
        • Ribes-Koninckx C.
        • et al.
        Imbalance in the composition of the duodenal microbiota of children with coeliac disease.
        J Med Microbiol. 2007; 56: 1669-1674
        • Lebwohl B.
        • Spechler S.J.
        • Wang T.C.
        • et al.
        Use of proton pump inhibitors and subsequent risk of celiac disease.
        Dig Liver Dis. 2014; 46: 36-40
        • Lebwohl B.
        • Blaser M.J.
        • Ludvigsson J.F.
        • et al.
        Decreased risk of celiac disease in patients with Helicobacter pylori colonization.
        Am J Epidemiol. 2013; 178: 1721-1730
        • Robinson K.
        • Kenefeck R.
        • Pidgeon E.L.
        • et al.
        Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses.
        Gut. 2008; 57: 1375-1385
        • Walter J.
        • Ley R.
        The human gut microbiome: ecology and recent evolutionary changes.
        Annu Rev Microbiol. 2011; 65: 411-429
        • Rawls J.F.
        • Mahowald M.A.
        • Ley R.E.
        • et al.
        Reciprocal gut microbiota transplants from zebrafish and mice to germ-free recipients reveal host habitat selection.
        Cell. 2006; 127: 423-433
        • Kwok C.S.
        • Arthur A.K.
        • Anibueze C.I.
        • et al.
        Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis.
        Am J Gastroenterol. 2012; 107: 1011-1019
        • Janarthanan S.
        • Ditah I.
        • Adler D.G.
        • et al.
        Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis.
        Am J Gastroenterol. 2012; 107: 1001-1010
        • Dial S.
        • Delaney J.A.
        • Barkun A.N.
        • et al.
        Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.
        JAMA. 2005; 294: 2989-2995
        • Dial S.
        • Delaney J.A.
        • Schneider V.
        • et al.
        Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy.
        CMAJ. 2006; 175: 745-748
        • Dial S.
        • Alrasadi K.
        • Manoukian C.
        • et al.
        Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies.
        CMAJ. 2004; 171: 33-38
        • Buendgens L.
        • Bruensing J.
        • Matthes M.
        • et al.
        Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea.
        J Crit Care. 2014; 29: 696.e11-696.e15
        • Chitnis A.S.
        • Holzbauer S.M.
        • Belflower R.M.
        • et al.
        Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011.
        JAMA Intern Med. 2013; 173: 1359-1367
        • Rao A.
        • Jump R.L.
        • Pultz N.J.
        • et al.
        In vitro killing of nosocomial pathogens by acid and acidified nitrite.
        Antimicrob Agents Chemother. 2006; 50: 3901-3904
        • Wilson K.H.
        • Sheagren J.N.
        • Freter R.
        Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster.
        J Infect Dis. 1985; 151: 355-361
        • Kelly C.P.
        • LaMont J.T.
        Clostridium difficile–more difficult than ever.
        N Engl J Med. 2008; 359: 1932-1940
        • De La Cochetiere M.F.
        • Durand T.
        • Lepage P.
        • et al.
        Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge.
        J Clin Microbiol. 2005; 43: 5588-5592
        • Yu Y.H.
        • Han D.S.
        • Choi E.Y.
        • et al.
        Is use of PPIs related to increased intraepithelial lymphocytes in the colon?.
        Dig Dis Sci. 2012; 57: 2669-2674
        • Poullis A.
        • Foster R.
        • Mendall M.A.
        • et al.
        Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity.
        Eur J Gastroenterol Hepatol. 2003; 15 ([author reply: 574]): 573-574
        • Rechkemmer G.
        • Frizzell R.A.
        • Halm D.R.
        Active potassium transport across guinea-pig distal colon: action of secretagogues.
        J Physiol. 1996; 493: 485-502
        • Freedberg D.E.
        • Salmasian H.
        • Friedman C.
        • et al.
        Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients.
        Am J Gastroenterol. 2013; 108: 1794-1801
        • Linsky A.
        • Gupta K.
        • Lawler E.V.
        • et al.
        Proton pump inhibitors and risk for recurrent Clostridium difficile infection.
        Arch Intern Med. 2010; 170: 772-778
        • Manges A.R.
        • Labbe A.
        • Loo V.G.
        • et al.
        Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease.
        J Infect Dis. 2010; 202: 1877-1884
        • Vincent C.
        • Stephens D.A.
        • Loo V.G.
        • et al.
        Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium difficile infection.
        Microbiome. 2013; 1: 18
        • Jakobsson H.E.
        • Jernberg C.
        • Andersson A.F.
        • et al.
        Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome.
        PLoS One. 2010; 5: e9836
        • Garcia-Mazcorro J.F.
        • Suchodolski J.S.
        • Jones K.R.
        • et al.
        Effect of the proton pump inhibitor omeprazole on the gastrointestinal bacterial microbiota of healthy dogs.
        FEMS Microbiol Ecol. 2012; 80: 624-636
        • Kanno T.
        • Matsuki T.
        • Oka M.
        • et al.
        Gastric acid reduction leads to an alteration in lower intestinal microflora.
        Biochem Biophys Res Commun. 2009; 381: 666-670